AdvanDx introduces LNA-based in vitro diagnostic test

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

AdvanDx of Woburn, Mass., has released its vanA/B Evigene in Europe. The new test is a locked nucleic acid (LNA)-based in vitro diagnostic test for detecting the antibiotic resistant “Superbugs,” vancomycin-resistant enterococci (VRE) and vancomycin-resistant staphylococcus aureus (VRSA) in positive blood cultures and clinical isolates.

According to AdvanDx, an in vitro molecular diagnostic provider, vanA/B Evigene combines the specificity of LNA probes with Evigene, a signal amplified sandwich hybridization assay platform, to detect both the vanA and vanB genes that confer VRE and VRSA.